About FDA

DDI Webinar Series: FDA Post-Marketing Drug Safety Surveillance- March 7, 2017

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all healthcare professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!

 
On March 7, 2017, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Post-Marketing Drug Safety Surveillance. Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems. This presentation provided an overview of pharmacovigilance and FDA’s pharmacovigilance activities.
 
 
 
Activity Outline and Continuing Education Information: FDA Post-Marketing Drug Safety Surveillance (PDF - 41KB)

If you have never attended an Adobe Connect meeting before:

Test your connection: https://collaboration.fda.gov/common/help/en/support/meeting_test.htm

Get a quick overview: http://www.adobe.com/go/connectpro_overview 

Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

Page Last Updated: 03/14/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English